Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Peter MacCallum Cancer Centre, East Melbourne, Australia

Survival: 13.6 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: Australia
City/State/Province: East Melbourne
Hospital: Peter MacCallum Cancer Centre
Journal: Link
Date: 2/2014

This phase 3 study involved metastatic melanoma patients with a mutation in the BRAF gene who had not received prior treatment. Patients were divided into two treatment groups. Group A consisted of 337 patients with a median age of 56 years, 59% of whom were male. Group B had 338 patients with a median age of 52.5 years, 54% of whom were male.

Patients in group A were treated with vemurafenib, a biologic therapy agent that is an inhibitor of the BRAF protein.

Patients in group B received chemotherapy with dacarbazine.

There were eight unspecified grade 5 adverse events reported for group A. Grade 4 neutropenia and liver toxicity were also reported.

There were seven unspecified grade 5 adverse events reported for group B. Grade 4 neutropenia was also reported.

The median overall survival rates for groups A and B were 13.6 and 9.7 months, respectively.

This study was supported by Hoffmann-La Roche-Genentech, a pharmaceutical company.

Correspondence: Dr. Grant A McArthur; email:

E-mail to a Friend Email Physician More Information